FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064599134> ?p ?o ?g. }

• W2064599134 endingPage "P56" @default.
• W2064599134 startingPage "P55" @default.
• W2064599134 abstract "The objective of this single-center, investigator-blinded study involving 157 randomized, healthy patients was to determine the dermal safety of a new 10% sodium sulfacetamide and 5% sulfur cleanser, compared with (10% sodium sulfacetamide and 5% sulfur) and 0.2% sodium lauryl sulfate (SLS). This study involved 3 phases. In the first phase, induction/irritation, the cleansers in 8% dilution and SLS were applied under separate semi-occlusive patches on the backs of subjects 3 times per week for 3 weeks. Each application remained on the skin for 8 hours, after which the patient washed it off. The test sites were observed 48 hours later (72 hours on weekends) for signs of irritation or inflammation. The second phase involved a rest period of 10 to 14 days, during which no patches were applied. During the third challenge phase, the cleansers were applied to new sites on the back for 48 hours. After patch removal, the sites were observed for signs of sensitization. Very few reactions were observed with any of the test products. There were no observed cases of contact sensitization, and there were only rare incidences of mild irritant reactions. 10% sodium sulfacetamide and 5% sulfur cleanser cleanser was not associated with any signs of irritation. 10% sodium sulfacetamide and 5% sulfur cleanser is the first fragrance-free sulfacetamide/sulfur cleanser for use in patients with rosacea. This study demonstrates that this newest cleanser has a very low potential for irritation or sensitization. Introduction: Patients with rosacea frequently have exquisitely sensitive skin.1 Therefore, it is important to prescribe therapeutic cleansers for these patients to minimize skin irritation.2 Antimicrobial cleansers containing 10% sodium sulfacetamide and 5% sulfur constitute the newest category of therapeutic cleanser. There are several antimicrobial cleaners presently available. All these formulations contain sodium cocoyl isethionate as the major surfactant, have a slightly acidic to neutral pH, and lack the odor problems of older sulfur-containing formulations.3-5 A major difference between 10% sodium sulfacetamide and 5% sulfur cleanser and the other cleansers is that 10% sodium sulfacetamide and 5% sulfur cleanser lacks fragrances3-5 that can cause skin irritation.1 Study design: The objective of this study was to assess dermal safety of a 10% sodium sulfacetamide and 5% sulfur cleanser by determining the cumulative irritation and contact hypersensitivity. This was a single-center, investigator-blinded study involving 157 randomized, healthy patients. Twenty patients dropped out before study completion. The dermal safety of 10% sodium sulfacetamide and 5% sulfur cleanser was compared with that of (10% sodium sulfacetamide and 5% sulfur) and 0.2% sodium lauryl sulfate (SLS). This low-dose SLS was used as a control. This study involved 3 phases. In the first phase, induction/irritation, the cleansers in 8% dilution and SLS were applied under separate semi-occlusive patches on the backs of subjects 3 times per week for 3 weeks. Each application remained on the skin for 8 hours, after which the patient washed it off. The test sites were observed 48 hours later (72 hours on weekends) for signs of irritation or inflammation. The second phase involved a rest period of 10 to 14 days during which no patches were applied. During the third challenge phase, the cleansers were applied to new sites on the back for 48 hours. After patch removal, the sites were observed for signs of sensitization. A 6-point grading scale was used to assess skin irritation (Table 1). Table 1Grading System for Skin Irritation0No sign of irritation0.5Barely perceptible erythema1Slight erythema2Noticeable erythema with slight infiltration3Erythema with marked edema4Erythema with edema and blistering Open table in a new tab Results: Very few irritant or sensitization reactions were observed with any of the test products. There were no observed cases of contact sensitization and there were only rare incidences of mild irritant reactions. 10% sodium sulfacetamide and 5% sulfur cleanser was not associated with any signs of irritation during either the induction or challenge phases (Table 2). During the induction phase, 10% sodium sulfacetamide and 5% sulfur) and 0.2% sodium lauryl sulfate (SLS) was associated with a few reactions (Table 3). One subject experienced barely perceptible erythema at day 22. Another subject experienced erythema with edema and blistering on day 4. When the patch was moved, the original patch site improved, showing noticeable erythema with slight infiltration on day 8. This reaction resolved by day 22. During the challenge phase, one subject receiving 10% sodium sulfacetamide and 5% sulfur) and 0.2% sodium lauryl sulfate (SLS) evidenced noticeable erythema with slight infiltration. However, a repeat challenge did not produce any reactions. Subjects receiving SLS did not show any reactions during the induction phase. This was expected, since this low-dose SLS served as a positive control. SLS was not used during the challenge phase.Table 2Irritant Reactions With 10% sodium sulfacetamide and 5% sulfurcleanser During the Induction Phase (N = 137)Score00.51234Number of subjects0000000 Open table in a new tab Table 3Irritant Reactions With Plexion Cleanser During the Induction Phase (N = 137)Score00.51234Number of subjects11 Open table in a new tab Conclusion: 10% sodium sulfacetamide and 5% sulfur cleanser is the first fragrance-free sodium sulfacetamide/sulfur cleanser for use in patients with rosacea. This study demonstrates that this newest antimicrobial cleanser has a very low potential for irritation or sensitization. Sodium sulfacetamide/sulfur cleansers are a well-tolerated therapeutic adjunct for patients with rosacea." @default.
• W2064599134 created "2016-06-24" @default.
• W2064599134 creator A5056671457 @default.
• W2064599134 creator A5083527914 @default.
• W2064599134 creator A5086774470 @default.
• W2064599134 date "2004-03-01" @default.
• W2064599134 modified "2023-09-27" @default.
• W2064599134 title "Dermal tolerability and safety of a fragrance-free sulfacetamide/sulfur cleanser" @default.
• W2064599134 doi "https://doi.org/10.1016/j.jaad.2003.10.213" @default.
• W2064599134 hasPublicationYear "2004" @default.
• W2064599134 type Work @default.
• W2064599134 sameAs 2064599134 @default.
• W2064599134 citedByCount "0" @default.
• W2064599134 crossrefType "journal-article" @default.
• W2064599134 hasAuthorship W2064599134A5056671457 @default.
• W2064599134 hasAuthorship W2064599134A5083527914 @default.
• W2064599134 hasAuthorship W2064599134A5086774470 @default.
• W2064599134 hasBestOaLocation W20645991341 @default.
• W2064599134 hasConcept C142724271 @default.
• W2064599134 hasConcept C16005928 @default.
• W2064599134 hasConcept C197934379 @default.
• W2064599134 hasConcept C203014093 @default.
• W2064599134 hasConcept C2776217527 @default.
• W2064599134 hasConcept C2777063393 @default.
• W2064599134 hasConcept C2778375690 @default.
• W2064599134 hasConcept C2780941728 @default.
• W2064599134 hasConcept C3019129585 @default.
• W2064599134 hasConcept C71924100 @default.
• W2064599134 hasConcept C98274493 @default.
• W2064599134 hasConceptScore W2064599134C142724271 @default.
• W2064599134 hasConceptScore W2064599134C16005928 @default.
• W2064599134 hasConceptScore W2064599134C197934379 @default.
• W2064599134 hasConceptScore W2064599134C203014093 @default.
• W2064599134 hasConceptScore W2064599134C2776217527 @default.
• W2064599134 hasConceptScore W2064599134C2777063393 @default.
• W2064599134 hasConceptScore W2064599134C2778375690 @default.
• W2064599134 hasConceptScore W2064599134C2780941728 @default.
• W2064599134 hasConceptScore W2064599134C3019129585 @default.
• W2064599134 hasConceptScore W2064599134C71924100 @default.
• W2064599134 hasConceptScore W2064599134C98274493 @default.
• W2064599134 hasIssue "3" @default.
• W2064599134 hasLocation W20645991341 @default.
• W2064599134 hasOpenAccess W2064599134 @default.
• W2064599134 hasPrimaryLocation W20645991341 @default.
• W2064599134 hasRelatedWork W1978720113 @default.
• W2064599134 hasRelatedWork W2000001951 @default.
• W2064599134 hasRelatedWork W2032790632 @default.
• W2064599134 hasRelatedWork W2296239473 @default.
• W2064599134 hasRelatedWork W2349424896 @default.
• W2064599134 hasRelatedWork W2355107996 @default.
• W2064599134 hasRelatedWork W2412991801 @default.
• W2064599134 hasRelatedWork W2622251978 @default.
• W2064599134 hasRelatedWork W3091965829 @default.
• W2064599134 hasRelatedWork W2993210647 @default.
• W2064599134 hasVolume "50" @default.
• W2064599134 isParatext "false" @default.
• W2064599134 isRetracted "false" @default.
• W2064599134 magId "2064599134" @default.
• W2064599134 workType "article" @default.